Volume 6, Issue 3, May 2018, Page: 64-68
Protective Effect of KTMon Streptozotocin-Induced Diabetic Symptoms and Their Potential Mechanisms in Rats
Baozhong Diao, Department of Formulation Branch, Liaocheng People's Hospital, Liaocheng, China
Weirong Jin, Department of Formulation Branch, Liaocheng People's Hospital, Liaocheng, China
Feng E. Zhang, Department of Emergency, Liaocheng People's Hospital, Liaocheng, China
Wenzhou Zhang, Department of Pharmacy, Liaocheng People's Hospital, Liaocheng, China
Received: Mar. 26, 2018;       Accepted: Apr. 12, 2018;       Published: May 24, 2018
DOI: 10.11648/j.ajcem.20180603.11      View  926      Downloads  35
Abstract
objective: The present study aimed to evaluate the therapeutic effects of ketangmin (KTM) on streptozotocin-(STZ) induced diabetic symptoms and their potential mechanisms. Methods: The effect of KTM on body weight, blood glucose, damaged pancreafic β-cells, oxidative stresses, proinflammatory cytokines, and glucose metabolizing enzymes in liver was studied. Results: The results show that administration of KTM can restore abnormal oxidative indices near normal levels. The STZ-damaged pancreatic β-cells of the rats were partly recovered gradually after the mice were administered with KTM 6 weeks later. Therefore, we may assume that KTM is effective in the protection of STZ-induced diabetic rats and KTM may be of use as antihyperglycemic agent.
Keywords
Ketangmin (KTM), Streptozotocin-Induced Diabetic Symptoms, Potential Mechanisms
To cite this article
Baozhong Diao, Weirong Jin, Feng E. Zhang, Wenzhou Zhang, Protective Effect of KTMon Streptozotocin-Induced Diabetic Symptoms and Their Potential Mechanisms in Rats, American Journal of Clinical and Experimental Medicine. Vol. 6, No. 3, 2018, pp. 64-68. doi: 10.11648/j.ajcem.20180603.11
Copyright
Copyright © 2018 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Reference
[1]
Frank L. Bowling, S. Preventing and treating foot complications associated with diabetes mellitus. Nature Reviews Endocrinology 11,606–616, (2015)
[2]
T. Vetrichelvan, M. Jegadeesan, and B. A. U. Devi. "Anti-diabetic activity of alcoholic extract of Celosia argentea LINN. seed in rats," Biological and Pharmaceutical Bulletin, vol. 25, no. 4, pp.526-528, 2002.
[3]
Naoto Egawa, Yingsong Lin, Taku Tabata et al., ABO blood type, long-standing diabetes, and the risk of pancreatic cancer. World J Gastroenterol. 2013 Apr 28; 19(16): 2537–2542.
[4]
Bharti SK, Krishnan S, Kumar A. Phytotherapy for diabetes mellitus: back to nature. Minerva Endocrinol. 2015 Nov 12.
[5]
Szarka A1, Horemans N, Passarella S et al. Demonstration of an intramitochondrial invertase activity and the corresponding sugar transporters of the inner mitochondrial membrane in Jerusalem artichoke (Helianthus tuberous L.) tubers. Planta. 2008 Oct; 228(5):765-75.
[6]
M. W Massing, C. A. Sueta, M. Chowdhury, D. P. Biggs, and R. J. Simpson Jr., "Lipid manage-ment among coronary artery disease patients with diabetes mellitus or advanced age," The American Journal of Cardiology, vol. 87, no. 5, pp. 646-649, 2001.
[7]
S. A. Metz, "Oxygenation products of antimonic acid: third messengers of insulin release," Prostaglandins, vol. 27, pp. 147-151, 1984.
[8]
V Chen and C. D. Ianuzzo, "Dosage effects of streptococci on rat tissue enzyme activities and glycogen concentration; Canadian Journal of Physiology and Pharmacology, vol. 60, no. 10, pp. 1251-1256,1982.
[9]
A. R. Chaudry, M. Alam, M. Ahmad, F. Z. Khan, and N. Nomani, "Studies on medicinal herbs. II: effect of Colchicum luteumonbio chemical parameters of rabbit serum; Fitoterapia, vol. 64, no. 6, pp. 510-515, 1993.
[10]
M. Y Donath and S. E. Shoelson, "Type 2 diabetes as an inflammatory disease; Nature Re-views Immunology, vol. ll, no. 2, pp. 98-107, 2011.
[11]
A. Chawla, K. D. Nguyen, and Y P. S. Goh, "Macrophage mediated inflammation in metabolic disease; Nature Reviews Immunology, vol. 11, no. 11, pp. 738-749, 2011.
[12]
J. Spranger, A. Kroke, M. Mohlig et al., "Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam study" Diabetes, vol. 52, no. 3, pp. 812-817, 2003.
[13]
G. S. Hotamisligil, P. Arner, J. F. Caro, R. L. Atkinson, and B. M. Spiegelman, "Increased adi-pose tissue expression of tumor necrosis factor-a in human obesity and insulin resistance," Journal of Clinical Investigation, vol. 95, no. 5, pp. 2409-2415, 1995.
[14]
C. Cavelti-Weder, A. Babians-Brunner, C. Keller et al., "Effects of grievously on glycemia and inflammatory markers in type 2 diabetes; Diabetes Care, vol. 35, no. 8, pp.1654-1662, 2012.
Browse journals by subject